Alexis Krumme: Raising Awareness of Alloantibody Diseases in Pregnancy
Alexis Krumme, Director, Global Epidemiology, Immunology Therapy Area at Johnson & Johnson Innovative Medicine, shared a post on LinkedIn:
“This week, I’m proud to recognize High Risk Pregnancy Awareness Week and the maternal-fetal medicine and OBGYN communities working to support families facing complex pregnancies.
Alloantibody-driven diseases can cause serious, life-threatening complications for babies and pregnant individuals, but awareness and understanding remain limited.
At Johnson & Johnson Innovative Medicine, we’re proud to be advancing the field of maternal-fetal immunology, with a focus on driving awareness of hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Together with the broader patient, prenatal diagnostic, and healthcare communities, we are working toward solutions that meet the real needs of individuals and their families navigating high-risk pregnancies, including those impacted by alloantibody diseases like HDFN and FNAIT.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 16:51Suzan Nakasendwa: A Growing Stroke Challenge in Uganda
-
Oct 20, 2026, 16:38Steve Moon: How Does Smoking Cessation Duration Affect Ischemic Stroke Risk
-
Oct 20, 2026, 16:25Cedrice Mentor: Reducing Platelet Wastage Through Cold Storage
-
Oct 20, 2026, 16:09Thirunavukkarasu Angappan: Can a Purified Fibrinogen Concentrate Replace Cryoprecipitate
-
Oct 20, 2026, 16:01Kalyan Roy: Platelet Conservation Through Evidence-Based Transfusion Practice
-
Oct 20, 2026, 15:28Stacy E. Croteau: 33 Countries, One Mission – Better Bleeding Disorder Care
-
Oct 20, 2026, 15:19Teresa Barnes: What Does a Pulmonary Embolism Mean for Jalen Hurts?
-
Oct 20, 2026, 15:04Laura S.: Could Speaking Up Prevent Maternal Deaths from Thrombosis?
-
Oct 20, 2026, 14:44Pete Stibbs: VTE in Professional Athletes – When Fitness Is Not Enough